STOCK TITAN
  1. Home
  2. News
  3. BNTX

BioNTech SE - BNTX STOCK NEWS

Welcome to our dedicated news page for BioNTech SE (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech SE.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioNTech SE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioNTech SE's position in the market.

News
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
Rhea-AI Summary
BioNTech SE (Nasdaq: BNTX) will report its first-quarter 2024 financial results on May 6, 2024. The Company will host a conference call and webcast to discuss the results and provide a corporate update for investors, financial analysts, and the general public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences earnings
-
News
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
Rhea-AI Summary
BioNTech SE announces three-year follow-up data of autogene cevumeran in pancreatic cancer patients, showing promising T cell responses and delayed tumor recurrence. The lead candidate is being evaluated in Phase 2 trials for multiple cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Rhea-AI Summary
BioNTech reports strong financial results for Q4 and full year 2023, with €3.8 billion in revenues and a net profit of €930.3 million. The company aims for ten oncology indication approvals by 2030 and anticipates a revenue guidance of €2.5-€3.1 billion for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
earnings
News
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
Rhea-AI Summary
BioNTech SE appoints Annemarie Hanekamp as Chief Commercial Officer, bringing extensive pharmaceutical experience to drive global commercialization strategy and prepare for oncology product launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
management
-
News
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
Rhea-AI Summary
BioNTech SE to present clinical trial data for oncology pipeline candidates at AACR Annual Meeting 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
conferences clinical trial
-
News
BioNTech Announces Planned Retirement of Sean Marett
Rhea-AI Summary
BioNTech SE announces the retirement of Chief Business and Commercial Officer, Sean Marett, who will transition to a specialist advisor role. A new Chief Commercial Officer will be appointed by July 1, 2024. Marett's responsibilities will be transferred to James Ryan, Ph.D. BioNTech acknowledges Marett's crucial role in fundraising, business development, and product commercialization, leading to the Company's growth and global expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
News
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
Rhea-AI Summary
BioNTech SE will announce its financial results for the full year and fourth quarter 2023 on March 20, 2024. The Company will host a conference call and webcast to discuss its financial results and provide a corporate update. Investors, financial analysts, and the general public can access the live conference call and webcast via the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences earnings
-
News
BIONTECH INVESTOR DEADLINE APPROACHING
Rhea-AI Summary
Faruqi & Faruqi, LLP is investigating potential claims against BioNTech SE (BNTX) for violations of federal securities laws. The complaint alleges that BioNTech overstated demand for Comirnaty, leading to significant inventory write-offs. Financial results showed a decrease in revenue, causing a drop in BioNTech's stock price. Pfizer's lower-than-expected utilization led to a non-cash charge for inventory write-offs, affecting BioNTech's financials as well.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
-
News
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 
Rhea-AI Summary
BioNTech and Autolus announced a strategic collaboration to advance their autologous CAR-T programs towards commercialization. BioNTech will invest $200 million in Autolus and secure the right to utilize Autolus' manufacturing capacity to accelerate the development of BNT211 into pivotal trials in CLDN6+ tumors. They will also support the launch and expansion of Autolus' lead cell therapy candidate obe-cel and have co-commercialization options for Autolus' AUTO1/22 and AUTO6NG programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
News
BIONTECH SHAREHOLDER ACTION REMINDER
Rhea-AI Summary
Faruqi & Faruqi, LLP is investigating potential claims against BioNTech SE (NASDAQ: BNTX) following a federal securities class action lawsuit. The complaint alleges that BioNTech overstated demand for Comirnaty and its commercial prospects, leading to significant inventory write-offs and other charges related to Comirnaty. The company's financial results for the second quarter of 2022 and full year 2022 showed a year-over-year decrease in revenue and earnings-per-share, causing the stock price to fall. Additionally, Pfizer's lower-than-expected utilization for COVID products resulted in a non-cash charge, leading to a reduction in BioNTech's revenue expectations for Comirnaty in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
Stock BNTX logo
BioNTech SE

Nasdaq:BNTX

BNTX Rankings

#492 Ranked by Market Cap
#4040 Ranked by Stock Gains
N/A Ranked by Dividends

BNTX Stock Data

20.81B
88.96M
62.84%
18.33%
1.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Germany
Mainz

About BNTX

everyone achieves greatness at biontech! as one of the most rapidly growing biotechnology companies in europe, we’re working on revolutionary approaches in the fight against cancer and other diseases. over 400 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. you too can become a pioneer! http://biontech.de/ http://biontech.de/imprint/